M. Tolaymat

Potential Role for Combined Subtype-Selective Targeting of M1 and M3 Muscarinic Receptors in Gastrointestinal and Liver Diseases

J. Raufman, G. Xie, M. Tolaymat, 2021, Frontiers in Pharmacology.

Overcoming Obstacles to Targeting Muscarinic Receptor Signaling in Colorectal Cancer

J. Raufman, G. Xie, Shien Hu, 2021, International journal of molecular sciences.

The Role of M3 Muscarinic Receptor Ligand-Induced Kinase Signaling in Colon Cancer Progression

J. Raufman, G. Xie, Shien Hu, 2019, Cancers.

Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring

R. Cross, S. Brown, M. Tolaymat, 2020, Crohn's & colitis 360.

The Impact of Intermediate Antidrug Antibodies to Infliximab and Adalimumab on Clinical Outcomes in Patients with Crohn’s Disease or Ulcerative Colitis

R. Cross, M. Tolaymat, Chaoyang Wang, 2022, European Medical Journal.

Prevalence and Risk Factors for Choledocholithiasis After Cholecystectomy: 72

Monjur Ahmed, C. Kistler, M. Tolaymat, 2017 .

Randomized controlled pilot study of feasibility and effectiveness of peer led remote Mindfulness‐Based Art Workshops on stress, anxiety, and depression in medical students

Chaoyang Wang, R. Cross, S. Quezada, 2022, Psychology in the Schools.

Muscarinic receptor agonist-induced βPix binding to β-catenin promotes colon neoplasia

J. Raufman, G. Xie, A. Chahdi, 2023, Scientific reports.